{"filing":{"accession_number":"0001213900-26-090746","cik":"0001139685","ticker":"AIDX","company_name":"20/20 Biolabs, Inc.","form":"8-K","filing_date":"2026-08-17","report_date":"2026-08-17","primary_document":"ea0302153-8k_2020bio.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1139685/000121390026090746/ea0302153-8k_2020bio.htm"},"events":[{"id":28238,"run_id":25819,"accession_number":"0001213900-26-090746","anchor_item_number":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The 8-K discloses under Item 2.02 the Company's financial results for Q2 2026 ended June 30, 2026, with a press release attached as Exhibit 99.1. The press release reports Q2 revenue of $0.7 million (up 36.5% YoY), gross profit of $0.3 million (up 86.6% YoY), and gross margin expansion to 41.7% from 30.5%, along with operational highlights including state-funded firefighter screening programs and cash position strengthening to $4.5 million. This is a standard quarterly earnings disclosure material to investors assessing the registrant's financial performance and trajectory.","company_name":"20/20 Biolabs, Inc.","ticker":"AIDX","filing_date":"2026-08-17","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":30116,"accession_number":"0001213900-26-090746","item_number":null,"item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The 8-K discloses under Item 2.02 the Company's financial results for Q2 2026 ended June 30, 2026, with a press release attached as Exhibit 99.1. The press release reports Q2 revenue of $0.7 million (up 36.5% YoY), gross profit of $0.3 million (up 86.6% YoY), and gross margin expansion to 41.7% from 30.5%, along with operational highlights including state-funded firefighter screening programs and cash position strengthening to $4.5 million. This is a standard quarterly earnings disclosure material to investors assessing the registrant's financial performance and trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T20:07:14.550366+00:00","company_name":"20/20 Biolabs, Inc.","ticker":"AIDX","filing_date":"2026-08-17"}]}